Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -99.93% | -194.19% | -190.40% | -25.74% | 14.16% |
| Total Depreciation and Amortization | 266.67% | 92.42% | 0.00% | 0.00% | -95.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12,441.69% | 15,320.60% | 5,693.77% | 0.61% | -75.40% |
| Change in Net Operating Assets | 453.64% | 83.77% | -290.41% | 120.62% | -114.22% |
| Cash from Operations | -10.28% | -6.12% | -55.29% | -18.90% | -10.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 287.06% | 736.14% | -1,732.18% | -85.19% | -0.82% |
| Cash from Investing | 287.06% | 735.74% | -1,732.18% | -85.19% | -0.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.01% | -- | 19,936,800.00% | 181,900.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.02% | -- | 72,282.84% | 181,900.00% | 9,111.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 486.73% | 348.84% | 1,075.71% | -116.77% | 135.73% |